327 related articles for article (PubMed ID: 16821082)
1. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers.
Ooe A; Kato K; Noguchi S
Breast Cancer Res Treat; 2007 Mar; 101(3):305-15. PubMed ID: 16821082
[TBL] [Abstract][Full Text] [Related]
2. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer.
Kim SJ; Miyoshi Y; Taguchi T; Tamaki Y; Nakamura H; Yodoi J; Kato K; Noguchi S
Clin Cancer Res; 2005 Dec; 11(23):8425-30. PubMed ID: 16322305
[TBL] [Abstract][Full Text] [Related]
3. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
Glück S; Ross JS; Royce M; McKenna EF; Perou CM; Avisar E; Wu L
Breast Cancer Res Treat; 2012 Apr; 132(3):781-91. PubMed ID: 21373875
[TBL] [Abstract][Full Text] [Related]
4. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
Martin M; Romero A; Cheang MC; López García-Asenjo JA; García-Saenz JA; Oliva B; Román JM; He X; Casado A; de la Torre J; Furio V; Puente J; Caldés T; Vidart JA; Lopez-Tarruella S; Diaz-Rubio E; Perou CM
Breast Cancer Res Treat; 2011 Jul; 128(1):127-36. PubMed ID: 21465170
[TBL] [Abstract][Full Text] [Related]
5. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
6. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
7. Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents.
Tassone P; Blotta S; Palmieri C; Masciari S; Quaresima B; Montagna M; D'Andrea E; Eramo OP; Migale L; Costanzo F; Tagliaferri P; Venuta S
Int J Oncol; 2005 May; 26(5):1257-63. PubMed ID: 15809716
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced tumor gene expression changes in human breast cancers.
Lee SC; Xu X; Lim YW; Iau P; Sukri N; Lim SE; Yap HL; Yeo WL; Tan P; Tan SH; McLeod H; Goh BC
Pharmacogenet Genomics; 2009 Mar; 19(3):181-92. PubMed ID: 19352302
[TBL] [Abstract][Full Text] [Related]
9. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
10. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling.
Maxwell PJ; Longley DB; Latif T; Boyer J; Allen W; Lynch M; McDermott U; Harkin DP; Allegra CJ; Johnston PG
Cancer Res; 2003 Aug; 63(15):4602-6. PubMed ID: 12907638
[TBL] [Abstract][Full Text] [Related]
11. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
12. RPN2 gene confers docetaxel resistance in breast cancer.
Honma K; Iwao-Koizumi K; Takeshita F; Yamamoto Y; Yoshida T; Nishio K; Nagahara S; Kato K; Ochiya T
Nat Med; 2008 Sep; 14(9):939-48. PubMed ID: 18724378
[TBL] [Abstract][Full Text] [Related]
13. The role of p53 mutations in bilateral breast carcinoma.
Ackerman J; Baunoch DA; Gimotty P; George J; Lane MA; Dawson PJ
Mod Pathol; 1995 Apr; 8(3):244-8. PubMed ID: 7617647
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between expressions of telomerase genes and apoptosis related genes in mammary ductal atypical hyperplasia].
Song M; Li BL; Mi XY; Gao YX; Song JY
Ai Zheng; 2002 May; 21(5):484-8. PubMed ID: 12452037
[TBL] [Abstract][Full Text] [Related]
15. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers.
Arai T; Miyoshi Y; Kim SJ; Akazawa K; Maruyama N; Taguchi T; Tamaki Y; Noguchi S
Eur J Surg Oncol; 2008 Jul; 34(7):734-8. PubMed ID: 17764884
[TBL] [Abstract][Full Text] [Related]
16. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
17. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
18. Normal p53 status and function despite the development of drug resistance in human breast cancer cells.
Wosikowski K; Regis JT; Robey RW; Alvarez M; Buters JT; Gudas JM; Bates SE
Cell Growth Differ; 1995 Nov; 6(11):1395-403. PubMed ID: 8562478
[TBL] [Abstract][Full Text] [Related]
19. Induction of p53 up-regulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer.
Middelburg R; de Haas RR; Dekker H; Kerkhoven RM; Pohlmann PR; Fuentes-Alburo A; Mohar A; Pinedo HM; Lankelma J
Clin Cancer Res; 2005 Mar; 11(5):1863-9. PubMed ID: 15756011
[TBL] [Abstract][Full Text] [Related]
20. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
